Predictive value of modeled AUCAFP-hCG, a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor

Urology

Volumn 76, Issue 2, 2010, Pages

  You, Benoit ^a   Fronton, Ludivine ^a   Boyle, Helen ^a   Droz, Jean Pierre ^a   Girard, Pascal ^a   Tranchand, Brigitte ^a   Ribba, Benjamin ^a   Tod, Michel ^a   Chabaud, Sylvie ^a   Coquelin, Henri ^a   Fléchon, Aude ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE;

AREA UNDER THE CURVE; ARTICLE; FOLLOW UP; GERM CELL TUMOR; HALF LIFE TIME; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONSEMINOMATOUS GERM CELL TUMORS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 77955712192     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.02.049     Document Type: Article

References (20)

1. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers International Germ Cell Cancer Collaborative Group J Clin Oncol 15 1997 594 603
2. G.C. Toner Early identification of therapeutic failure in nonseminomatous germ cell tumors by assessing serum tumor marker decline during chemotherapy: still not ready for routine clinical use J Clin Oncol 22 2004 3842 3845
3. B.A. Murphy, R.J. Motzer, and M. Mazumdar Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy Cancer 73 1994 2520 2526
4. R.J. Motzer, M. Mazumdar, and S.C. Gulati Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Natl Cancer Inst 85 1993 1828 1835 (Pubitemid 23333615)
5. R.J. Motzer, M. Mazumdar, and D.F. Bajorin High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors J Clin Oncol 15 1997 2546 2552
6. K. Fizazi, S. Culine, and A. Kramar Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors J Clin Oncol 22 2004 3868 3876
7. R. de Wit, R. Sylvester, and C. Tsitsa Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer Br J Cancer 75 1997 432 435
8. S.E. Inanc, R. Meral, and E. Darendeliler Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors Acta Oncol 38 1999 505 509
9. M. Mazumdar, D.F. Bajorin, and J. Bacik Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy J Clin Oncol 19 2001 2534 2541
10. G.C. Toner, N.L. Geller, and C. Tan Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors Cancer Res 50 1990 5904 5910
11. P.H. Willemse, D.T. Sleijfer, and K.H. Schraffordt The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis Oncodev Biol Med 2 1981 129 134
12. B. You, P. Perrin, and G. Freyer Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy Clin Biochem 41 2008 785 795
13. B. You, P. Girard, and P. Paparel Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy Prostate 69 2009 1325 1333
14. You B, Pollet-Villard M, Boyle H, et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol. (in press, doi:10.1093/annonc/mdq033 ).
15. R. de Wit, L. Collette, and R. Sylvester Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1998 1350 1355
16. A. Horwich, and M.J. Peckham Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis Cancer Treat Rep 70 1986 1329 1331
17. S.L. Beal, L.B. Sheiner, and A. Boeckmann NONMEM users guides 2006 Icon Development Solutions Ellicott City, MD
18. Y. Yano, S.L. Beal, and L.B. Sheiner Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 2001 171 192
19. C. Massard, H. Huguet, and A. Kramar Cross-validation of new prognostic index integrating tumor marker decline in patients with relapsed disseminated germ cell tumors Proc Am Soc Clin Oncol 2009 J Clin Oncol 27 Suppl 2009 5086
20. S. Olofsson, O. Dahl, and M. Jerkeman Individualized intensification of treatment based on tumor marker decline in metastatic nonseminomatous germ cell testicular cancer (NSGCT): A report from the Swedish Norwegian Testicular Group, SWENOTECA Proc Am Soc Clin Oncol 2009 J Clin Oncol 27 Suppl 2009 5015